Consistently, treatment with G4 stabilizing ligands, a cationic phthalocyanine tetrakis-(diisopropyl-guanidine) phthalocyanine (Zn-DIGP), and TMPyP4, targeting the promoters of KRAS and HRAS, decreased RAS expression in cancer cells (Figure 4A) [59,60]. Here, KRAS is linked to cancer.